An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Colorectal cancer is the second most common cancer, representing 13% of all diagnosed cancers. Cetuximab is a recombinant chimeric monoclonal IgG1 antibody and epidermal growth factor receptor (EGFR) inhibitor. Cetuximab is approved for the first-line treatment in combination with chemotherapy or as a single agent in patients who have failed or are intolerant to chemotherapy in patients with EGFR-expressing, RAS wild-type metastatic colorectal cancer. Cetuximab efficacy emerged from studies that were conducted to approve the drug. Cetuximab is well tolerated; its toxicities are caused by its mechanism of action and the most common adverse reaction is skin toxicity. The main purpose of this manuscript is to present an update on the evidence-based summary of efficacy and safety and on the cost-effectiveness of cetuximab. Furthermore, it suggests a management of adverse drug reactions to improve the tolerability of the drug.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cetuximab specifically binds epidermal growth factor receptor (EGFR) and blocks the EGFR signaling pathway, thereby exerting anti-tumor activity [132].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [132]
Citations
Cites
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Maughan, T. S., Adams, R. A., Smith, C. G., Meade, A. M., Seymour, M. T., Wilson, R. H., Idziaszczyk, S., Harris, R., Fisher, D., Kenny, S. L., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60613-2 · Cited by 960
Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A., Schrag, D., Greene, C., O'Neil, B. H., Atkins, J. N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7105 · Cited by 898
Van Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Tejpar, S., Stintzing, S., Ciardiello, F., Tabernero, J., Van Cutsem, E., Beier, F., Esser, R., Lenz, H.-J., & Heinemann, V. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3797 · Cited by 709
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
Missiaglia, E., Jacobs, B., D'Ario, G., Di Narzo, A. F., Soneson, C., Budinska, E., Popovici, V., Vecchione, L., Gerster, S., Yan, P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu275 · Cited by 646
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer
Corcoran, R. B., André, T., Atreya, C. E., Schellens, J. H. M., Yoshino, T., Bendell, J. C., Hollebecque, A., McRee, A. J., Siena, S., Middleton, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1226 · Cited by 592
Pirker, R., Pereira, J. R., von Pawel, J., Krzakowski, M., Ramlau, R., Park, K., de Marinis, F., Eberhardt, W. E., Paz-Ares, L., Störkel, S., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70318-7 · Cited by 576
Sorich, M. J., Wiese, M. D., Rowland, A., Kichenadasse, G., McKinnon, R. A., & Karapetis, C. S. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu378 · Cited by 540
Holch, J. W., Ricard, I., Stintzing, S., Modest, D. P., & Heinemann, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.007 · Cited by 534
Tveit, K. M., Guren, T., Glimelius, B., Pfeiffer, P., Sorbye, H., Pyrhonen, S., Sigurdsson, F., Kure, E., Ikdahl, T., Skovlund, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0915 · Cited by 533
Price, T. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. S., Thomas, A., Tjulandin, S., Zhang, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70118-4 · Cited by 473
Lacouture, M. E., Anadkat, M. J., Bensadoun, R.-J., Bryce, J., Chan, A., Epstein, J. B., Eaby-Sandy, B., Murphy, B. A., & MASCC Skin Toxicity Study Group (2011) · Supportive Care in Cancer · doi:10.1007/s00520-011-1197-6 · Cited by 444
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319
Peterson, D. E., Boers-Doets, C. B., Bensadoun, R. J., & Herrstedt, J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv202 · Cited by 299
FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
Bokemeyer, C., Köhne, C.-H., Ciardiello, F., Lenz, H.-J., Heinemann, V., Klinkhardt, U., Beier, F., Duecker, K., van Krieken, J. H., & Tejpar, S. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.04.007 · Cited by 256
Piessevaux, H., Buyse, M., Schlichting, M., Van Cutsem, E., Bokemeyer, C., Heeger, S., & Tejpar, S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8532 · Cited by 222
Exclusion of Kaposi Sarcoma From Analysis of Cancer Burden—Reply
Fitzmaurice, C., & Naghavi, M. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1747 · Cited by 189
Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines
Roselló, S., Blasco, I., Fabregat, L. G., Cervantes, A. M. R., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx216 · Cited by 168
The biological properties of cetuximab
Vincenzi, B., Schiavon, G., Silletta, M., Santini, D., & Tonini, G. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.07.006 · Cited by 164
Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion
Potthoff, K., Hofheinz, R., Hassel, J. C., Volkenandt, M., Lordick, F., Hartmann, J. T., Karthaus, M., Riess, H. B., Lipp, H., Hauschild, A., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq387 · Cited by 129
Pinto, C., Barone, C. A., Girolomoni, G., Russi, E. G., Merlano, M. C., Ferrari, D., & Maiello, E. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0298 · Cited by 129
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer
Chan, D. L. H., Segelov, E., Wong, R. S., Smith, A., Herbertson, R. A., Li, B. T., Tebbutt, N., Price, T., & Pavlakis, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007047.pub2 · Cited by 114
Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
Lenz, H. (2006) · PubMed · Cited by 108
Guren, T. K., Thomsen, M., Kure, E. H., Sorbye, H., Glimelius, B., Pfeiffer, P., Österlund, P., Sigurdsson, F., Lothe, I. M. B., Dalsgaard, A. M., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.93 · Cited by 74
BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies
van Brummelen, E. M. J., de Boer, A., Beijnen, J. H., & Schellens, J. H. M. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0031 · Cited by 68
Modest, D. P., Stintzing, S., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al‐Batran, S., Heintges, T., Kahl, C., Seipelt, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22396 · Cited by 58
Huxley, N., Crathorne, L., Varley‐Campbell, J., Tikhonova, I. A., Snowsill, T., Briscoe, S., Peters, J., Bond, M. L., Napier, M., & Hoyle, M. (2017) · Health Technology Assessment · doi:10.3310/hta21380 · Cited by 48
Emerging treatment options for BRAF-mutant colorectal cancer
Ursem, C., Atreya, C. E., & Van Loon, K. (2018) · Gastrointestinal Cancer: Targets and Therapy · doi:10.2147/gictt.s125940 · Cited by 47
Hofheinz, R.-D., Segaert, S., Safont, M. J., Demonty, G., & Prenen, H. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.032 · Cited by 42
Gabbay, M. B., Ring, A., Byng, R., Anderson, P., Taylor, R. S., Matthews, C., Harris, T., Berry, V., Byrne, P., Carter, E., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21350 · Cited by 41
Shankaran, V., Ortendahl, J. D., Purdum, A., Bolinder, B., Anene, A. M., Sun, G. H., & Bentley, T. G. K. (2015) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000231 · Cited by 40
Cetuximab in the management of colorectal cancer.
Lenz, H. (2007) · PubMed Central · Cited by 40
Cutsem, E. V., Cuyle, P.-J. A., Huijberts, S. C. F. A., Yaeger, R. D., Schellens, J. H. M., Élez, E., Tabernero, J. M., Fakih, M., Montagut, C. O., Peeters, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.4_suppl.627 · Cited by 36
Role of cetuximab in first-line treatment of metastatic colorectal cancer
Sotelo, M. J., García-Paredes, B., Aguado, C., Sastre, J., & Díaz-Rubio, E. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i15.4208 · Cited by 35
Chan, D. L. H., Pavlakis, N., Shapiro, J. D., Price, T. J., Karapetis, C. S., Tebbutt, N. C., & Segelov, E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135599 · Cited by 29
Cao, D., Xu, H., Xu, X., & Ge, W. (2017) · Oncotarget · doi:10.18632/oncotarget.19022 · Cited by 25
Carvalho, A. C., Leal, F. R. P., & Sasse, A. D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175409 · Cited by 20
Kotake, M., Aoyama, T., Munemoto, Y., Doden, K., Kataoka, M., Kobayashi, K., Nishimura, G., Fujita, H., Nakamura, K., Takehara, A., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.5505 · Cited by 14
First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients
Moiseyenko, V. M., Moiseenko, F. V., Yanus, G. A., Kuligina, E. S., Соколенко, А. П., Валерьевич, Б. И., Кудрявцев, А. А., Алексахина, С. Н., Volkov, N., Chubenko, V. A., et al. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0629-1 · Cited by 10
Cost-effectiveness of cetuximab for colorectal cancer
Park, T., Choi, C.-J., Choi, Y., & Suh, D. (2016) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2016.1245618 · Cited by 8
Chan, D. L. H., Pavlakis, N., Shapiro, J. D., Price, T. J., Karapetis, C. S., Tebbutt, N. C., & Segelov, E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138916 · Cited by 7
Brasky, T. M., White, E., & Chen, C. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.4688 · Cited by 3
Combination Drug Development in BRAF Mutant Colorectal Cancer
Lam, M. S., Pant, S., & Yap, T. A. (2018) · Oncoscience · doi:10.18632/oncoscience.399 · Cited by 1
Cited by
Stefani, C., Miricescu, D., Stanescu-Spinu, I.-I., Nica, R. I., Greabu, M., Totan, A. R., & Jinga, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910260 · Cited by 402
Insights into the success and failure of systemic therapy for hepatocellular carcinoma
Bruix, J., da Fonseca, L. G., & Reig, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0179-x · Cited by 220
Colorectal cancer: Recent advances in management and treatment
Fadlallah, H., El Masri, J., Fakhereddine, H., Youssef, J., Chemaly, C., Doughan, S., & Abou-Kheir, W. (2024) · World Journal of Clinical Oncology · doi:10.5306/wjco.v15.i9.1136 · Cited by 169
“Cetuximab thus prevents downstream phosphorylation and activation of kinases, leading to decreased cell proliferation and migration, as well as induction of apoptosis[97].”
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Dey, A., Mitra, A., Pathak, S., Prasad, S. V., Sun-Zhang, A., Zhang, H., Sun, X., & Banerjee, A. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231178403 · Cited by 125
“Monotherapy with cetuximab is an option for metastatic colorectal cancer patients with EGFR-expressing, K-Ras wild-type tumors who resist chemotherapy.(127,128)”
Background
Metadata
- Authors
- Fornasier, G., Francescon, S., & Baldo, P.
- Affiliations
- Centro di Riferimento Oncologico (IT)
- Corresponding author
- Fornasier, Giulia
- Venue
- Advances in Therapy
- Published
- 2018-09-14
- Volume
- 35
- Issue
- 10
- Pages
- 1497-1509
- ISSN
- 0741-238X (ISSN-L)
- 1865-8652
- OpenAlex
- W2891193646
- Cited by
- 134
- References
- 55
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 10 · 2023: 20 · 2022: 53 · 2021: 17 · 2020: 9 · 2019: 8
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Advances in Therapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Foundation for Anesthesia Education and Research
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- cetuximab, metastatic colorectal cancer, EGFR inhibitors, RAS wild-type, first-line therapy, combination chemotherapy, second-line therapy, drug toxicity, skin toxicity, cost-effectiveness, adverse drug reaction management, monoclonal antibodies
- MeSH terms
- Cetuximab, Antineoplastic Agents, Immunological, Humans, Neoplasm Staging, Colorectal Neoplasms, Treatment Outcome, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.